SEARCH:   Advanced

Blood, 1 August 2007, Vol. 110, No. 3, pp. 972-978. Prepublished online as a Blood First Edition Paper on March 30, 2007; DOI 10.1182/blood-2007-01-067769. This Article Full Text Full Text (PDF) All Versions of this Article: blood-2007-01-067769v1 110/3/972    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Park, S. Articles by Kim, W. S. Search for Related Content PubMed PubMed Citation Articles by Park, S. Articles by Kim, W. S. Related Collections Neoplasia Clinical Trials and Observations Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma Sarah Park1, Jeeyun Lee1, Young Hyeh Ko2, Arum Han1, Hyun Jung Jun1, Sang Chul Lee1, In Gyu Hwang1, Yeon Hee Park1, Jin Seok Ahn1, Chul Won Jung1, Kihyun Kim1, Yong Chan Ahn3, Won Ki Kang1, Keunchil Park1, and Won Seog Kim1 1 Division of Hematology-Oncology, Department of Medicine 2 Department of Pathology, and 3 Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea To define prognostic impact of Epstein-Barr virus (EBV) infection in diffuse large B-cell lymphoma (DLBCL), we investigated EBV status in patients with DLBCL. In all, 380 slides from paraffin-embedded tissue were available for analysis by EBV-encoded RNA-1 (EBER) in situ hybridization, and 34 cases (9.0%) were identified as EBER-positive. EBER positivity was significantly associated with age greater than 60 years (P = .005), more advanced stage (P < .001), more than one extranodal involvement (P = .009), higher International Prognostic Index (IPI) risk group (P = .015), presence of B symptom (P = .004), and poorer outcome to initial treatment (P = .006). The EBER+ patients with DLBCL demonstrated substantially poorer overall survival (EBER+ vs EBER– 35.8 months [95% confidence interval (CI), 0-114.1 months] vs not reached, P = .026) and progression-free survival (EBER+ vs EBER– 12.8 months [95% CI, 0-31.8 months] vs 35.8 months [95% CI, 0-114.1 months], respectively (P = .018). In nongerminal center B-cell–like subtype, EBER in situ hybridization positivity retained its statistical significance at the multivariate level (P = .045). Nongerminal center B-cell–like patients with DLBCL with EBER positivity showed substantially poorer overall survival with 2.9-fold (95% CI, 1.1-8.1) risk for death. Taken together, DLBCL patients with EBER in situ hybridization+ pursued more rapidly deteriorating clinical course with poorer treatment response, survival, and progression-free survival. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: Effect of EBV in Diffuse Large B-Cell Lymphoma Journal Watch Oncology and Hematology, August 14, 2007; 2007(814): 1 - 1. [Full Text]

	Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020